Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

Clinical trial NCT07450183 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07450183
Sponsor: Henry Ford Health System
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer (NSCLC)

Start date: 2027-01-01
Primary completion: 2027-12-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.